LASIK project is underway

Article

A recent LASIK panel symposium has revealed the progresses and plans for the LASIK Quality of Life Collaboration Project.

A recent LASIK panel symposium has revealed the progresses and plans for the LASIK Quality of Life Collaboration Project.

The study, conducted by the US Food and Drug Administration (FDA), National Eye Institute (NEI) and the US Department of Defence (DoD), analyses the patient-reported outcomes of LASIK surgery.

Dr David W. Parke, American Academy of Ophthalmology (AAO) CEO, said: "LASIK has proven to be safe and effective and has high patient satisfaction rates. We expect that a LASIK quality of life study, relying on sound science and relevant clinical experiences, will be able to shed new light on the post-LASIK patient experience."

The FDA, the AAO and the American Society for Cataract and Refractive Surgery (ASCRS) discussed the project's present developments, anticipated developments and the study's phases.

In phase one patient-reported outcomes were assessed with a web-based questionnaire. Phase two will be a clinical study of military personnel called Patient-Reported Outcomes with LASIK (PROWL-1). The subjects will be questioned preoperatively and then at 1, 3 and 6 months postoperatively. The last phase will be named PROWL-2 and will consist of a national multicentre clinical study.

Various studies published suggest that 95% of patients are satisfied with LASIK outcomes. Initial problems with LASIK have been glare, halos and dry-eye.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.